This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bussolino, F. Search for Related Content PubMed PubMed Citation Articles by Bussolino, F. Related Collections Related Article

(Circulation Research. 2006;99:231.)
© 2006 American Heart Association, Inc.

Editorials

Small Molecule Approaches for Promoting Ischemic Tissue Vascularization

Federico Bussolino

From the Department of Oncological Sciences and Institute for Cancer Research and Treatment, Division of Molecular Angiogenesis, University of Torino, Candiolo, Italy.

Correspondence to Federico Bussolino, MD, PhD, Institute for Cancer Research and Treatment, Department of Oncological Sciences, Division of Molecular Angiogenesis, Strada Provincale 142, Candiolo (Torino) 10060, Italy. E-mail federico.bussolino@ircc.it

See related article, pages 257–265

Key Words: steroids • integrin • VEGF • cyclooxigenase-2 • therapeutic angiogenesis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Angiogenesis and arteriogenesis identify 2 specific processes that lead to the formation of new capillaries and the development of collateral vessels from pre-existing arterioles, respectively. Both processes characterize tissue repair and remodeling occurring in acute and chronic ischemic vascular diseases, and both processes represent the final targets of therapeutic angiogenesis aimed at providing an alternative treatment strategy for patients with lower limb ischemia and coronary artery disease.^1,2

Angiogenesis and arteriogenesis are driven by distinct, but partially overlapping, cellular and molecular pathways. Whereas the role of hypoxia and angiogenic inducers seems to be the trigger for pathological angiogenesis (ie, tumors, inflammatory chronic diseases, retinal maculopathy), fluid shear stress might be the most important stimulus for initiation of arteriogenesis.^1,2 Besides these specific initial triggers, angiogenesis and arteriogenesis share growth factors, chemokines, proteases, inflammatory cells, and bone marrow-derived cells, which play quantitatively different roles in sustaining and refining these mechanisms of vascularization. A paradigmatic example of these differences is the differing roles played by inflammatory cells in angiogenesis and arteriogenesis. In fact, angiogenesis may also occur in the absence of leukocyte recruitment. On the contrary, fluid shear stress activates the expression of multiple genes in endothelial cells (EC) aimed mainly to trigger the attraction and adhesion of circulating blood cells, which are necessary and sufficient functions to maintain arteriogenesis.

In the last 10 years, relevant strides have been made with respect to therapeutic angiogenesis. Proof-of-concept evidence for therapeutic growth factor, both gene and protein-mediated neovascularization, was provided in animal models of chronic myocardial . . . [Full Text of this Article]

Related Article:

Identification of Sokotrasterol Sulfate As a Novel Proangiogenic Steroid

Siun Murphy, Bruno Larrivée, Ingrid Pollet, Kyle S. Craig, David E. Williams, Xin-Hui Huang, Megan Abbott, Fred Wong, Cameron Curtis, Thomas P. Conrads, Timothy Veenstra, Mira Puri, York Hsiang, Michel Roberge, Raymond J. Andersen, and Aly Karsan
Circ. Res. 2006 99: 257-265. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				H. Senzaki Long-Term Outcome of Kawasaki Disease Circulation, December 16, 2008; 118(25): 2763 - 2772. [Full Text] [PDF]